<DOC>
	<DOCNO>NCT02197130</DOCNO>
	<brief_summary>This study 26 week , randomize , parallel group , double blind comparison PF-02545920 5 mg , PF-02545920 20 mg , placebo dose BID treatment motor impairment subject Huntington 's Disease . A total approximately 260 subject plan randomize study . Primary endpoint change baseline Total Motor Score ( TMS ) assessment Unified Huntington Disease Rating Scale ( UHDRS ) 26 week treatment . secondary endpoint include change baseline Total Maximum Chorea ( TMC ) score UHDRS 13 26 week treatment Clinical Global Impression-Improvement score 13 26 week treatment .</brief_summary>
	<brief_title>Randomized , Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>CAG repeat equal great 36 ; Total motor score equal great 10 ; Total functional capacity equal great 7 . Clinically significant neurologic disorder Huntington 's disease ; Other severe acute psychiatric condition , mania and/or psychosis ; History neutropenia , myeloproliferative disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Huntington ; chorea ; total motor score ; CAG repeat : total functional capacity ; motor cognitive behavioral symptom</keyword>
</DOC>